Summary
Approximately 1 in 4 therapeutic agents are marketed as racemic mixtures, the individual enantiomers of which frequently differ in both their pharmacodynamic and pharmacokinetic profiles. The use of racemates has become the subject of considerable discussion in recent years, and an area of concern for both the pharmaceutical industry and regulatory authorities. The use of single enantiomers has a number of potential clinical advantages, including an improved therapeutic/pharmacological profile, a reduction in complex drug interactions, and simplified pharmacokinetics. In a number of instances stereochemical considerations have contributed to an understanding of the observed pharmacological effects of a drug administered as a racemate. However, relatively little is known of the influence of patient factors (e.g. disease state, age, gender and genetics) on drug enantiomer disposition and action in man. Examples may also be cited where the use of single enantiomers, nonracemic mixtures and racemates of currently used agents may offer clinical advantages. The issues associated with drug chirality are complex and depend upon the relative merits of the individual agent. In the future it is likely that a number of existing racemates will be re-marketed as single enantiomer products with potentially improved clinical profiles and possible novel therapeutic indications.
Similar content being viewed by others
References
Ariens EJ, Wuis EW, Veringa EJ. Stereoselectivity of bioactive xenobiotics. A pre-Pasteur attitude in medicinal chemistry, pharmacokinetics and clinical pharmacology. Biochem Pharmacol 1988; 37: 9–18
Cushny AR. Biological relations of optically isomeric substances. London: Bailliere, Tindall and Cox, 1926
Mason S. The left hand of nature. New Scientist 1984; 101: 10–4
Matteson D. Through the chemical looking glass. New Scientist 1991; 132: 35–9
Hawkes N. Lateral thinking. Times Magazine: 5 Jun 1993: 30-1
Moran N. Drug firms sort their lefts from their rights. Independent on Sunday: 7 Nov 1993
Controulis J, Rebstock MC, Crooks HM. Chloramphenicol (chloromycetin) V. Synthesis. J Am Chem Soc 1949; 71: 2463–8
Rebstock MC, Crooks HM, Controulis J, et al. Chloramphenicol (chloromycetin) IV. Chemical studies. J Am Chem Soc 1949; 71: 2458–62
Ceccarini G, Maione AM. Variations of optical rotation of naproxen: polarimetric determination in the presence of non-chiral basic compounds. J Pharm Sci 1989; 78: 1053–4
Williams K, Lee E. Importance of drug enantiomers in clinical pharmacology. Drugs 1985; 30: 333–54
Cahn RS, Ingold CK, Prelog V. The specification of asymmetric configuration in organic chemistry. Experientia 1956; 12: 81–94
Easson LH, Stedman E. Studies on the relationship between chemical constitution and physiological action. V. Molecular dissymmetry and physiological activity. Biochem J 1933; 27: 1257–66
Lehmann PAF, De Miranda JFR, Ariens EJ. Stereoselectivity and affinity in molecular pharmacology. In: Jucker E, editor. Progress in drug research. Vol. 20. Basel: Birkhauser Verlag, 1976: 101–42
Lehmann PAF. Quantifying stereoselectivity or how to choose a pair of shoes when you have two left feet. Trend Pharmacol Sci 1982; 3: 103–6
Powell JR, Ambre JJ, Ruo TI. The efficacy and toxicity of drug stereoisomers. In: Wainer IW, Drayer DE, editors. Drug stereochemistry. Analytical methods and pharmacology. New York: Marcel Dekker, 1988: 245–70
Triggle DJ. On the other hand: the stereoselectivity of drug action at ion channels. Chirality 1994; 6: 58–62
Caldwell J, Winter SM, Hutt AJ. The pharmacological and toxicological significance of the stereochemistry of drug disposition. Xenobiotica 1988; 18 Suppl. 1: 59–70
Tucker GT, Lennard MS. Enantiomer specific pharmacokinetics. Pharmacol Ther 1990; 45: 309–29
Levy RH, Boddy AV. Stereoselectivity in pharmacokinetics: a general theory. Pharm Res 1991; 8: 551–6
Ariens EJ. Stereochemistry, a basis for sophisticated nonsense in pharmacokinetics and clinical pharmacology. Eur J Clin Pharmacol 1984; 26: 663–8
Eichelbaum M. Pharmacokinetic and pharmacodynamic consequences of stereoselective drug metabolism in man. Biochem Pharmacol 1988; 37: 93–6
Longstreth JA. Verapamil. A chiral challenge to the pharmacokinetic and pharmacodynamic assessment of bioavailability and bioequivalence. In: Wainer IW, editor. Drug stereochemistry. Analytical methods and pharmacology. 2nd ed. New York: Marcel Dekker, 1993: 315–36
Vogelgesang B, Echizen H, Schmidt E, et al. Stereoselective first-pass metabolism of highly cleared drugs: studies of the bioavailability of L- and D-verapamil examined with a stable isotope technique. Br J Clin Pharmacol 1984; 18: 733–40
Echizen H, Vogelgesang B, Eichelbaum M. Effects of d, 1-verapamil on atrioventricular conduction in relation to its stereoselective first-pass metabolism. Clin Pharmacol Ther 1985; 38: 71–6
Coltart DJ, Shand DG. Plasma propranolol levels in the quantitative measurement of β-adrenergic blockade in man. BMJ 1970; 3: 731–4
Walle T, Webb JG, Bagwell EE, et al. Stereoselective delivery and actions of beta receptor antagonists. Biochem Pharmacol 1988; 37: 115–24
Walle T, Conradi EC, Walle UK, et al. 4-Hydroxypropranolol and its glucuronide after single and long-term doses of propranolol. Clin Pharmacol Ther 1980; 27: 22–31
Li G, Treiber G, Maier K, et al. Disposition of ibuprofen in patients with liver cirrhosis. Stereochemical considerations. Clin Pharmacokinet 1993; 25: 154–63
Avgerinos A, Hutt AJ. Interindividual variability in the enantiomeric disposition of ibuprofen following the oral administration of the racemic drug to healthy volunteers. Chirality 1990; 2: 249–56
Hutt AJ, Caldwell J. The metabolic chiral inversion of 2-arylpropionic acids — a novel route with pharmacological consequences. J Pharm Pharmacol 1983; 35: 693–704
Caldwell J, Hutt AJ, Fournel-Gigleux S. The metabolic chiral inversion and dispositional enantioselectivity of the 2-arylpropionic acids and their biological consequences. Biochem Pharmacol 1988; 37: 105–14
Williams KM. Enantiomers in arthritic disorders. Pharmacol Ther 1990; 46: 273–95
Evans AM. Enantioselective pharmacodynamics and pharmacokinetics of chiral non-steroidal antiinflammatory drugs. Eur J Clin Pharmacol 1992; 42: 237–56
Chen C-Y, Chen C-S. Stereoselective disposition of ibuprofen in patients with compromised renal haemodynamics. Br J Clin Pharmacol 1995; 40: 67–72
Chandler MHH, Scott SR, Blouin RA. Age associated stereoselective alterations in hexobarbital metabolism. Clin Pharmacol Ther 1988; 43: 436–41
Zhou H-H, Whelan E, Wood AJJ. Lack of effect of ageing on the stereochemical disposition of propranolol. Br J Clin Pharmacol 1992; 33: 121–3
Hooper WD, Qing MS. The influence of age and gender on the stereoselective metabolism and pharmacokinetics of mephobarbital in humans. Clin Pharmacol Ther 1990; 48: 633–40
Lennard MS, Tucker GT, Woods HF. Stereoselectivity in pharmacokinetics and drug metabolism. In: Taylor JB, editor. Comprehensive medicinal chemistry. Vol. 5. Biopharmaceutics. Oxford: Pergamon Press, 1990: 187–204
Lennard MS, Tucker GT, Silas JH, et al. Differential stereoselective metabolism of metoprolol in extensive and poor debrisoquin metabolisers. Clin Pharmacol Ther 1983; 34: 732–7
Walshe JM. Penicillamine, a new oral therapy for Wilson’s Disease. Am J Med 1956; 21: 487–95
Glatt H, Oesch F. Mutagenicity of cysteine and penicillamine and its enantiomeric selectivity. Biochem Pharmacol 1985; 34: 3725–8
Tu J-B, Blackwell RQ, Lee PF. D,L-Penicillamine as a cause of optic axial neuritis. J Am Med Ass 1963; 185: 83–6
Walshe JM. Chirality of penicillamine [letter]. Lancet 1992; 339: 254
Lee A, Lawton NF. Penicillamine treatment of Wilson’s disease and optic neuropathy. J Neurol Neurosurg Psych 1991; 58: 746
Blaschke G, Kraft HP, Fickentscher K et al. Chromatographische racemattrennung von thalidomid und teratogene Wirkung der enantiomere. Arzneimittelforschung 1979; 29: 1640–2
Scott WJ, Fradkin R, Wilson JG. Non-confirmation of thalido-mide-induced teratogenesis in rats and mice. Teratology 1977; 16: 333–6
Fabro S, Smith RL, Williams RT. Toxicity and teratogenicity of optical isomers of thalidomide. Nature 1967; 215: 269
Eriksson T, Bjorkman S, Roth B, et al. Stereospecific determination, chiral inversion in vitro and pharmacokinetics in humans of the enantiomers of thalidomide. Chirality 1995; 7: 44–52
Testa B, Carrupt P-A, Gal J. The so-called ‘interconversion’ of stereoisomeric drugs: an attempt at clarification. Chirality 1993; 5: 105–11
Banitt EH, Schmid JR, Newmark RA. Resolution of flecainide acetate, N-(2-piperidylmethyl)-2,5-bis (2,2,2-trifluoro-ethoxy) benzamide acetate and antiarrhythmic properties of the enantiomers. J Med Chem 1986; 29: 299–302
Hill RJ, Duff HJ, Sheldon RS. Determinants of stereospecific binding of type I antiarrhythmic drugs to cardiac sodium channels. Mol Pharmacol 1988; 34: 659–63
Gross AS, Mikus G, Fischer C, et al. Stereoselective disposition of flecainide in relation to the sparteine/debrisoquine meta-boliser phenotype. Br J Clin Pharmacol 1989; 28: 555–6
Richards R, Tattersfield AE. Bronchial β-adrenoceptor blockade following eyedrops of timolol and its isomer L-714, 465 in normal subjects. Br J Clin Pharmacol 1985; 20: 459–62
Fraunfelder FT, Barker AF. Respiratory effects of timolol. N Engl J Med 1985; 311: 1441
Baldwin JJ, Abrams WB. Stereochemically pure drugs, an industrial perspective. In: Wainer IW, Drayer DE, editors. Drug stereochemistry. Analytical methods and pharmacology. New York: Marcel Dekker, 1988: 311–56
Chiou GCW, Zhao F, Shen Z-H et al. Effects of D-timolol and L-timolol on ocular blood flow and ocular blood pressure. J Ocular Pharmacol 1990; 6: 23–9
Lanning CF, Harmel MH. Ketamine anesthesia. Ann Rev Med 1975; 26: 137–41
Eastman D, Hickey M, Hickey F. Ketamine misuse identified. Pharm J 1992; 248: 444
White PF, Schutter J, Shafer A, et al. Comparative pharmacology of the ketamine isomers. Br J Anaesth 1985; 57: 197–203
White PF, Ham J, Way WL, et al. Pharmacology of ketamine isomers in surgical patients. Anaesthesiology 1980; 52: 231–9
Vlasses PH, Irvin JD, Huber PB, et al. Pharmacology of the enantiomers and (−)-p-OH metabolite of indacrinone. Clin Pharmacol Ther 1981; 29: 798–807
Tobert JA, Cirillo VJ, Hitzenberger G, et al. Enhancement of uricosuric properties of indacrinone by manipulation of the enantiomer ratio. Clin Pharmacol Ther 1981: 29: 344–50
Gottesman MM, Paston I. Resistance to multiple chemotherapeutic agents in human cancer cells. Trend Pharmacol Sci 1988; 9: 54–8
Plumb JA, Milroy R, Kaye SB. The activity of verapamil as a resistance modifier in vitro in drug resistant human tumour cell lines is not stereospecific. Biochem Pharmacol 1990; 39: 787–92
Advani SV, Singh BN. Pharmacodynamic, pharmacokinetic and antiarrhythmic properties of d-sotalol, the dextro-isomer of sotalol. Drugs 1995: 49: 664–79
Colatsky TJ. Antiarrhythmic drugs: where are we going? Pharmaceutical News 1995; 2: 17–23
De Camp WH. The FDA perspective on the development of stereoisomers. Chirality 1989; 1: 2–6
Cayen MN. Racemic mixtures and single stereoisomers: industrial concerns and issues in drug development. Chirality 1991; 3: 94–8
Rauws AG, Groen K. Current regulatory (draft) guidance on chiral medicinal products: Canada, EEC, Japan, United States. Chirality 1994; 6: 72–5
Brown JR. Stereochemical principles. Drug Info J 1990; 24: 117–20
Ariens EJ. Stereochemistry: a source of problems in medicinal chemistry. Med Res Rev 1986; 6: 451–66
Millership JS, Fitzpatrick A. Commonly used chiral drugs: a survey. Chirality 1993; 5: 573–6
Shindo H, Caldwell J. Development of chiral drugs in Japan: an update on regulatory and industrial opinion. Chirality 1995; 7: 349–52
Shindo H, Caldwell J. Regulatory aspects of the development of chiral drugs in Japan: a status report. Chirality 1991; 3: 91–3
Baba T, Murabayashi S, Aoyagi K, et al. Effects of dilevalol, an R, R-isomer of labetalol, on blood pressure and renal function in patients with mild-to-moderate essential hypertension. Eur J Clin Pharmacol 1988; 35: 9–15
Brittain RT, Drew GM, Levy GP. The α and β-adrenoceptor blocking potencies of labetalol and its individual stereoisomers in anaesthetized dogs and in isolated tissues. Br J Pharmacol 1982; 77: 105–14
Anon. Neuromuscular blocking agent from Glaxo. Pharm J 1996; 256: 152
Sun Wai WYS, Flynn PJ. 51W89, the IR cis I’R cis isomer of atracurium. Anaesth Pharmacol Rev 1995; 3: 218–21
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Hutt, A.J., Tan, S.C. Drug Chirality and its Clinical Significance. Drugs 52 (Suppl 5), 1–12 (1996). https://doi.org/10.2165/00003495-199600525-00003
Published:
Issue Date:
DOI: https://doi.org/10.2165/00003495-199600525-00003